Daiichi Sankyo’s Humira Biosimilar Now Available in Japan

Daiichi Sankyo rolled out its biosimilar version of Humira (adalimumab) on May 26, in tune with its NHI price listing on the same day, as Japan’s second follow-on of AbbVie’s flagship anti-TNF-α antibody. Adalimumab BS Subcutaneous Injection “Daiichi Sankyo” will...read more